Orylmyte (Dermatophagoides Pteronyssinus, Dermatophagoides Farinae)

Dermatophagoides pteronyssinus and Dermatophagoides farinae, the active ingredients in Orylmyte, are a standardized allergen extract presented as a 1:100 w/v extract for subcutaneous injection use. They are employed in allergen immunotherapy to reduce symptoms of allergic rhinitis and asthma caused by house dust mite sensitivity.

GNH USA supplies Orylmyte as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Orylmyte is used in allergen immunotherapy targeting the house dust mite allergy pathway.

- Allergic rhinitis (dust mite): reduces nasal congestion, sneezing and itching. - Allergic asthma (dust mite): decreases bronchial hyper‑responsiveness and inhaler reliance. - Persistent allergic conjunctivitis (dust mite): alleviates eye itching and tearing.

Adverse reactions may occur following subcutaneous administration of Orylmyte.

Common Side Effects: - Local redness at injection site: mild erythema lasting a few hours. - Swelling at injection site: transient edema. - Itching at injection site: brief pruritus. - Low‑grade fever: temporary temperature rise. - Headache: mild discomfort. - Fatigue: short‑term tiredness.

Serious or Rare Side Effects: - Anaphylaxis: rapid onset of systemic allergic reaction. - Severe bronchospasm: acute airway narrowing. - Angio‑edema: swelling of lips, tongue or face. - Serum sickness‑like reaction: joint pain and rash. - Persistent urticaria: lasting hives beyond 24 hours. - Neurological symptoms: rare dizziness or paresthesia.

Prior to initiating therapy with Orylmyte, several safety considerations should be observed.

- Contraindication: avoid use in patients with a history of severe anaphylaxis to dust‑mite extracts. - Monitoring: observe patients for at least 30 minutes after each injection for systemic reactions. - Pregnancy: use only if clearly needed; limited data are available. - Breastfeeding: consider potential exposure to infant; weigh benefits versus risks. - Comorbid asthma: ensure asthma is well‑controlled before starting immunotherapy. - Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Orylmyte may interact with other agents that affect immune response or increase the risk of allergic reactions.

Major Interactions (Avoid): - Beta‑blockers: may mask anaphylaxis symptoms and hinder treatment. - ACE inhibitors: can exacerbate angio‑edema risk.

Moderate Interactions (Monitor Closely): - Antihistamines: may reduce local skin test reactivity, requiring timing adjustments. - Immunosuppressants: could diminish the efficacy of immunotherapy. - Other allergen extracts: concurrent administration may increase systemic reaction risk. - Live vaccines: schedule immunotherapy away from vaccine administration.